Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.

Autor:	Sng CCT; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Wong YNS; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; UCL Cancer Institute, University College London, London, United Kingdom., Wu A; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Ottaviani D; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Chopra N; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Galazi M; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Benafif S; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Soosaipillai G; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Roylance R; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom., Lee AJX; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; UCL Cancer Institute, University College London, London, United Kingdom., Shaw H; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2020 Nov 20; Vol. 10, pp. 595804. Date of Electronic Publication: 2020 Nov 20 (Print Publication: 2020).
DOI:	10.3389/fonc.2020.595804
Abstrakt:	Background: The COVID-19 pandemic remains a pressing concern to patients with cancer as countries enter the second peak of the pandemic and beyond. It remains unclear whether cancer and its treatment contribute an independent risk for mortality in COVID-19. Methods: We included patients at a London tertiary hospital with laboratory confirmed SARS-CoV-2 infection. All patients with a history of solid cancer were included. Age- and sex-matched patients without cancer were randomly selected. Patients with hematological malignancies were excluded. Results: We identified 94 patients with cancer, matched to 226 patients without cancer. After adjusting for age, ethnicity, and co-morbidities, patients with cancer had increased mortality following COVID-19 (HR 1.57, 95% CI:1.04-2.4, p = 0.03). Increasing age (HR 1.49 every 10 years, 95% CI:1.25-1.8, p < 0.001), South Asian ethnicity (HR 2.92, 95% CI:1.73-4.9, p < 0.001), and cerebrovascular disease (HR 1.93, 95% CI:1.18-3.2, p = 0.008) also predicted mortality. Within the cancer cohort, systemic anti-cancer therapy (SACT) within 60 days of COVID-19 diagnosis was an independent risk factor for mortality (HR 2.30, 95% CI: 1.16-4.6, p = 0.02). Conclusions: Along with known risk factors, cancer and SACT confer an independent risk for mortality following COVID-19. Further studies are needed to understand the socio-economic influences and pathophysiology of these associations. (Copyright © 2020 Sng, Wong, Wu, Ottaviani, Chopra, Galazi, Benafif, Soosaipillai, Roylance, Lee and Shaw.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu